353 related articles for article (PubMed ID: 35528835)
21. Mori Cortex extract ameliorates nonalcoholic fatty liver disease (NAFLD) and insulin resistance in high-fat-diet/streptozotocin-induced type 2 diabetes in rats.
Ma LL; Yuan YY; Zhao M; Zhou XR; Jehangir T; Wang FY; Xi Y; Bu SZ
Chin J Nat Med; 2018 Jun; 16(6):411-417. PubMed ID: 30047462
[TBL] [Abstract][Full Text] [Related]
22. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
24. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α.
Liu T; Luo X; Li ZH; Wu JC; Luo SZ; Xu MY
World J Gastroenterol; 2019 Sep; 25(36):5451-5468. PubMed ID: 31576092
[TBL] [Abstract][Full Text] [Related]
25. Effective Food Ingredients for Fatty Liver: Soy Protein β-Conglycinin and Fish Oil.
Yamazaki T; Li D; Ikaga R
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30567368
[TBL] [Abstract][Full Text] [Related]
26.
Zhang S; Luo H; Sun S; Zhang Y; Ma J; Lin Y; Yang L; Tan D; Fu C; Zhong Z; Wang Y
Front Pharmacol; 2021; 12():741871. PubMed ID: 35126100
[TBL] [Abstract][Full Text] [Related]
27. Network pharmacology-based approach to understand the effect and mechanism of Danshen against anemia.
He S; Wang T; Shi C; Wang Z; Fu X
J Ethnopharmacol; 2022 Jan; 282():114615. PubMed ID: 34509606
[TBL] [Abstract][Full Text] [Related]
28. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T; Ide T; Shimano H; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Yatoh S; Kitamine T; Okazaki H; Tamura Y; Sekiya M; Takahashi A; Hasty AH; Sato R; Sone H; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1240-54. PubMed ID: 12730331
[TBL] [Abstract][Full Text] [Related]
29. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
30. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.
Yang ZX; Shen W; Sun H
Hepatol Int; 2010 Aug; 4(4):741-8. PubMed ID: 21286345
[TBL] [Abstract][Full Text] [Related]
31. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
Duseja A; Singh SP; Saraswat VA; Acharya SK; Chawla YK; Chowdhury S; Dhiman RK; Jayakumar RV; Madan K; Misra SP; Mishra H; Modi SK; Muruganathan A; Saboo B; Sahay R; Upadhyay R
J Clin Exp Hepatol; 2015 Mar; 5(1):51-68. PubMed ID: 25941433
[TBL] [Abstract][Full Text] [Related]
32. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
33. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
[TBL] [Abstract][Full Text] [Related]
34. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Chen Q; Wang T; Li J; Wang S; Qiu F; Yu H; Zhang Y; Wang T
Nutrients; 2017 Jan; 9(2):. PubMed ID: 28146130
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
36. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
37. Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells.
Liu Y; Yu Q; Chen Y
Biomed Pharmacother; 2018 Dec; 108():716-723. PubMed ID: 30248539
[TBL] [Abstract][Full Text] [Related]
38. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
39. Total sesquiterpene glycosides from Loquat (Eriobotrya japonica) leaf alleviate high-fat diet induced non-alcoholic fatty liver disease through cytochrome P450 2E1 inhibition.
Jian T; Ao X; Wu Y; Lv H; Ma L; Zhao L; Tong B; Ren B; Chen J; Li W
Biomed Pharmacother; 2017 Jul; 91():229-237. PubMed ID: 28458161
[TBL] [Abstract][Full Text] [Related]
40. Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cytochrome P450 enzymes.
Zhou X; Chan K; Yeung JH
Drug Metabol Drug Interact; 2012 Mar; 27(1):9-18. PubMed ID: 22718621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
